Gnosis Receives CEP Certification for Teicoplanin - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Gnosis Receives CEP Certification for Teicoplanin


PTSM: Pharmaceutical Technology Sourcing and Management
Volume 10, Issue 6

The European Directorate for the Quality of Medicines (EDQM) has granted Gnosis a certificate of suitability of the European Pharmacopoeia (CEP) for teicoplanin. The CEP certification provides proof that the quality of the substances used in human medicines is suitably controlled by the relevant monographs of the European Pharmacopoeia.

Teicoplanin is a true fermentation glycopeptide antibiotic produced by actinoplanes teichomyceticus strains and is a mixture of glycopeptide components which are currently classified into six main subcomponents known as a specific “Complex”.

The first application for a generic of the reference product was submitted in 2005 through the decentralized procedure (DCP). During the teicoplanin assessment, it was discovered that the compositional profile of glycopeptide subcomponents present in the generic version differed compared to the originator. As the composition of the teicoplanin subcomponents is dependent upon the strain of microorganism and the fermentation conditions used, these may give rise to differences in the composition between the generic and reference product. In order to address the inconsistencies across the EU in terms of the requirements for generics of teicoplanin, a procedure was initiated in 2013 to ensure that the active substance is sufficiently characterized, new tests and limits were proposed, in addition to those currently specified in the monograph.

Gnosis has demonstrated the capability to obtain the same “Complex” profile of the originator, including specific ranges of subcomponents, being the first European company to obtain CEP in compliance with the new tests and limits.

Source: Gnosis

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here